Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/2005
06/02/2005US20050119458 Transport protein for use in identifying modulator for prevention and treatment of cell proliferative, skin and psychological disorders; anticonvulsants; insecticides; pesticides; anthelmintics
06/02/2005US20050119457 Human proteins
06/02/2005US20050119450 Biodegradable polyphosphoramidates for controlled release of bioactive substances
06/02/2005US20050119344 Based on the different degree of protection that ensure the blood-vessels of the healthy and of the tumor tissue against the influence of blood-coagulation enhancing substances; formic (methane) acid; antiseptic and bactericide
06/02/2005US20050119333 Compositions comprising ether compounds and pharmaceutical uses therefor
06/02/2005US20050119323 Hormone sensitive vcancer; antiproliferative agents ; induction apoptosis; angiotensin inhibitors
06/02/2005US20050119322 Phorboxazole derivatives for treating cancer
06/02/2005US20050119320 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
06/02/2005US20050119316 Semicarbazide derivatives and the use thereof as antithrombotics
06/02/2005US20050119305 N-hydroxy-6-[(4-phenylbenzoyl)amino]hexanamide; hydroxamic acid derivative and equivalent thereof; antiinflammatory, anticarcinogenic, antiarthritic, antidiabetic agents; sepsis, leukemia, osteoporosis, skin disorders, cachexia, autoimmune diseases, hepatitis, endometriosis; hypergammaglobulinemia
06/02/2005US20050119303 kit; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide; VEGF (endothelial growth factor)and FGF (fibroblast growth factor) receptor kinase inhibitors or antibody; integrin inhibitor; synergistic
06/02/2005US20050119291 Pyrimidine compounds
06/02/2005US20050119288 Dosing schedule for a novel anticancer agent
06/02/2005US20050119286 Beta-2'-or 3'-halonucleosides
06/02/2005US20050119280 1-[alkyl 1-[heteroaryl )alkyl] and 1-[ aryl) alkyl]-7-( pyrimidin-4-yl) imadazo [1,2-a] pyrimidin-5(1h)-one derivatives
06/02/2005US20050119274 3-[5-chloro-6-methyl-2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-4-( 1H-indol-3-yl)-pyrrole-2,5-dione; T lymphocytes, Protein Kinase C (PKC) and glycogen synthase kinase 3 beta (GSK3B) mediated diseases;
06/02/2005US20050119271 Pyrimidine A2B selective antagonist compounds, their synthesis and use
06/02/2005US20050119263 Synergistic mixture of n,n-diethyl, (2-(4-phenylnethyl)phenoxy) ethanamine and adriamycin
06/02/2005US20050119256 Aromatic amino acid derivates and medicinal compositions
06/02/2005US20050119254 Antitumor agents; using taurolidine; administering into lungs
06/02/2005US20050119250 Amino-derivatives as novel inhibitors of histone deacetylase
06/02/2005US20050119236 Cancer treatments and pharmaceutical compositions therefor
06/02/2005US20050119213 Vascular therapeutics
06/02/2005US20050119204 Osteopontin-related compositions and methods
06/02/2005US20050119201 Inhibitor of dna methylation
06/02/2005US20050119196 Remedies for lung cancer
06/02/2005US20050119193 Novel solid preparation containing block copolymer and anthracycline anticancer agent and process for producing the same
06/02/2005US20050118717 delivering to microtubules a microtubule binding substance, such as taxol, that is coupled to a herpes simplex virus 1 VP22 protein; may be used pharmaceutically to retard or arrest cell division of cells such as neoplastic cells or protozoal parasite cells in vitro or in vivo.
06/02/2005US20050118715 Modulation of stem and progenitor cell differentiation, assays, and uses thereof
06/02/2005US20050118696 Methods and means for modulating PGE synthase activity
06/02/2005US20050118656 Methods for diagnosis and treatment of epithelial-derived cancers
06/02/2005US20050118638 Using thyrotrophin (TSH) receptor as diagnostic tool in detection of autoimmune diseases; competive binding assay
06/02/2005US20050118290 Compositions and method for treatment of steroid/nuclear receptor-mediated diseases
06/02/2005US20050118255 non-hygroscopic, crystalline anhydrous maleate salt of 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene) methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
06/02/2005US20050118253 comprising a nucleic acid that is fully encapsulated within a lipid; for treating a neoplasia in a mammal
06/02/2005US20050118242 Using testosterone; topical applying to skins
06/02/2005US20050118232 N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
06/02/2005US20050118196 Novel therapeutic processes for establishing or enhancing an immunized state, and compositions useful therefor
06/02/2005US20050118184 Compositions and methods for enhancing the immunogenicity of antigens
06/02/2005US20050118178 Use of t-cell immune response cdna7 (tirc7) in angiogenic and anti-angiogenic therapy
06/02/2005US20050118168 Administering a compound which binds to a C-type lectin on the surface of a dendritic cell, with the proviso that the C-type lectin is not the DEC-205 receptor
06/02/2005US20050118165 useful for imaging such tumors; scintigraphic detection, diagnosis, prognosis, monitoring and therapy of Met-bearing tumors
06/02/2005US20050118150 Population of hematopoietic cells, made to exhibit a greater clonogenic potential, engraftment potential, immune system reconstitution potential and/or proportion of CD34+ positive cells by culturing with a transition metal compound that chelates copper such as tetraethylenepentamine
06/02/2005US20050118117 Methods for identifying risk of melanoma and treatments thereof
06/02/2005US20050116649 Low-pressure mercury vapor discharge lamp
06/02/2005DE10163098B4 Verfahren zur Hemmung der Replikation von Viren A method of inhibiting the replication of viruses
06/02/2005CA2807475A1 Inhibitors of the mutant form of kit
06/02/2005CA2747871A1 Compositions and methods for the treatment of tumor of hematopoietic origin
06/02/2005CA2546794A1 Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
06/02/2005CA2546566A1 Chimeric anti cd44 antibodies and their use for treating acute myeloid leukemia
06/02/2005CA2546237A1 Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
06/02/2005CA2546189A1 Inhibitors of the mutant form of kit
06/02/2005CA2545856A1 Compositions comprising antibodies and methods of using the same for targeted nanoparticulate active agent delivery
06/02/2005CA2545723A1 Use of cathepsin k inhibitors in severe bone loss diseases
06/02/2005CA2545717A1 Anti-tumour terpene compounds
06/02/2005CA2545054A1 Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
06/02/2005CA2545043A1 Combination therapy comprising the use of et-743 and doxorubicin for treating cancer
06/02/2005CA2544320A1 Method of treating cancer using a combination comprising et-743 and 5-fluorouracil
06/02/2005CA2542351A1 Combinational radiotherapy and chemotherapy compositions and methods
06/02/2005CA2542215A1 Screening assays and methods of tumor treatment
06/02/2005CA2528549A1 Use of epha4 and modulator of epha4 for diagnosis, treatment and prevention of cancer
06/01/2005EP1536010A1 Preventives/remedies for cancer
06/01/2005EP1536009A1 Hla-a24-restricted cancer antigen peptide
06/01/2005EP1536008A1 2’,5’-OLIGOADENYLATE PHOSPHODIESTERASE
06/01/2005EP1536006A1 Cancer antigens and utilization thereof
06/01/2005EP1535926A1 Carbacyclic phosphatidic acid derivative
06/01/2005EP1535915A1 Furan or thiophene derivative and medicinal use thereof
06/01/2005EP1535911A1 Metabolically inert anti-inflammatory and anti-tumor antifolates
06/01/2005EP1535910A1 Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
06/01/2005EP1535906A1 Nitrogen-containing compounds
06/01/2005EP1535903A1 Modified MscL protein channel
06/01/2005EP1535891A1 Remedy
06/01/2005EP1535624A1 Chronic myeloid leukemia (cml) therapy
06/01/2005EP1535623A1 Renal cell carcinoma treatment
06/01/2005EP1535622A1 Melanoma therapy
06/01/2005EP1535621A1 Agaricus blazei murill extract capable of preventing cancer induction or metastasis
06/01/2005EP1535610A1 Therapeutic agent for cancer
06/01/2005EP1535512A1 DISEASE MODEL ANIMAL CARRYING FOREIGN PPARa GENE TRANSFERRED THEREINTO AND USE THEREOF
06/01/2005EP1535067A2 PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE
06/01/2005EP1534847A1 Retroviral vector and stable packaging cell lines
06/01/2005EP1534823A2 The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates
06/01/2005EP1534744A1 Altered insulin-like growth factor binding proteins
06/01/2005EP1534726A2 Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
06/01/2005EP1534725A2 Compounds and methods for inhibiting selectin-mediated function
06/01/2005EP1534716A1 Heterobicyclic pyrazole derivatives as kinase inhibitors
06/01/2005EP1534715A1 Furopyridine and furopyrimidine derivatives for the treatment of hyper-proliferative disorders
06/01/2005EP1534712A2 Pyrazolo[1,5-a]pyrimidine compounds as cyclin dependent kinase inhibitors
06/01/2005EP1534710A1 Pyrazolopyrimidines as cyclin dependent kinase inhibitors
06/01/2005EP1534709A1 Pyrazolopyrimidines as cyclin dependent kinase inhibitors
06/01/2005EP1534708A2 Purine derivatives and their use as antiproliferative agents
06/01/2005EP1534706A1 Furanthiazole derivatives as heparanase inhibitors
06/01/2005EP1534695A2 Tyrosine kinase inhibitors
06/01/2005EP1534692A1 Urea derivatives as kinase inhibitors
06/01/2005EP1534687A1 Pyrimidine compounds
06/01/2005EP1534685A1 1h-indazole-3-carboxamide compounds as cyclin dependent kinases (cdk) inhibitors
06/01/2005EP1534681A1 Substituted quinoline ccr5 receptor antagonists
06/01/2005EP1534680A1 Prenylation inhibitors and methods of their synthesis and use
06/01/2005EP1534677A1 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1
06/01/2005EP1534676A1 Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
06/01/2005EP1534674A2 Cytotoxic agents containing novel potent taxanes and their therapeutic use
1 ... 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 ... 2211